Thirdly, we performed a more comprehensive analysis, including overall analysis and subgroup analyses grouped by age and COVID-19 cases, respectively, and further confirmed that the use of IL-17 inhibitors in psoriasis did not increase the risk of SARS-CoV-2 infection or worsen the course of COVID-19 compared with the use of non-biologics. Here, IL17A is linked to COVID-19.